TrialDigestive diseases and sciences2016

Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial.

Iris Dotan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.